Abstracts Archive - Page 189 of 2607 - ACR Meeting Abstracts

Abstract Number: PP15 • ACR Convergence 2024
Breathing Mindfully and How to Control Anxiety in Lupus Patients
Amanda Greene, Lupus Research Alliance, Los Angeles, CA
Background/Purpose: For over four decades, Systemic Lupus Erythematosus has impacted my Quality of Life.. I was diagnosed in 1983- my entire life was changed. I…
Abstract Number: 2640 • ACR Convergence 2024
Comparative Safety and Use of Non-conventional Combination Targeted Therapy in Adults with Psoriatic Arthritis
Alexander Wu¹, Arianna Zhang², Yujia Guo¹, Jialing Liu¹, Donghan Yang¹, Lourdes Perez Chada³, Alexis Ogdie⁴, Jose Scher⁵ and Joseph Merola⁶, ¹University of Texas Southwestern Medical Center, Dallas, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Wayland, MA, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵New York University School of Medicine, New York, NY, ⁶UT Southwestern Medical Center, Newton, MA
Background/Purpose: Psoriatic arthritis is a chronic systemic inflammatory disorder with significant impacts on health and life quality. Achieving good disease control in psoriatic arthritis (PsA)…
Abstract Number: 2684 • ACR Convergence 2024
Assessment of Skin in Patients with Systemic Sclerosis Using High Frequency Ultrasound : A Comparative Study with Histology and Clinical Parameters of Skin Disease
Ruhani Desai¹, Filemon Tan², Minghua Wu³, Jefferey Browning⁴, Samuel Theodore³, Meng Zhang³, Brian Skaug³, Maureen Mayes³ and Shervin Assassi³, ¹UTHealth Houston Division of Rheumatology, DeLand, FL, ²University of Texas at Houston McGovern Medical School, Houston, TX, ³UTHealth Houston Division of Rheumatology, Houston, TX, ⁴Boston Univeristy, Boston, MA
Background/Purpose: The extent of skin involvement and its rate of progression can provide prognostic information for systemic sclerosis (SSc)-related morbidity and mortality. Moreover, skin assessment…
Abstract Number: 2678 • ACR Convergence 2024
History of Cutaneous Lupus Promotes Blood and Skin Interferon Signatures in SLE Patients
Svenja Henning¹, Lam Tsoi², Craig Dobry², Celine Berthier², Benjamin Klein², Amy Hurst², Rachael Wasikowski³, Johann Gudjonsson² and J. Michelle Kahlenberg², ¹University of Groningen, Groningen, Netherlands, ²University of Michigan, Ann Arbor, MI, ³Michigan, Dept. of Dermatology, Ann Arbor, MI
Background/Purpose: Cutaneous lupus (CLE) can present in isolation or as one of the most common manifestations of systemic lupus erythematosus (SLE). Interferon (IFN) stimulated genes…
Abstract Number: 2627 • ACR Convergence 2024
Development and Validation of a Novel Score System to Guide Diagnostic Procedures in Children with Concerns of Chronic Nonbacterial Osteomyelitis
Rajdeep Pooni¹, Sarah Menashe², Melissa Oliver³, Anja Schnabel⁴, Eveline Wu⁵, Zhaoyi Wang⁶, Claire Yang⁷, Achille Marino⁸, Cassyanne Aguiar⁹, Johnathan Akikusa¹⁰, Ummusen Kaya Akca¹¹, Beverly Almeida¹², Simone Appenzeller¹³, Ozge Basaran¹⁴, Matthew Basiaga¹⁵, David Cabral¹⁶, Martina Capponi¹⁷, nathan Donaldson¹⁸, Bugra Egeli¹⁹, Emily Fox²⁰, Antonella insalaco²¹, Ramesh Iyer²², Annette Jansson²³, Inna Kostik²⁴, Mikhail Kostik²⁵, Leonard Kovalick²⁶, Katia Kozu²⁷, Sivia Lapidus²⁸, Tzielan Lee²⁹, Aleksander Lenert³⁰, Kamran Mahmood³¹, Edoardo Marrani³², Doaa Mosa³³, Alexander Mushkin³⁴, Farzana Nuruzzaman³⁵, Karen Onel³⁶, Manuela Pardeo²¹, Trang Pham²², Lauren Potts³⁷, Athimalaipet Ramanan³⁸, Angelo Ravelli³⁹, Nathan Rogers¹⁸, Ian Muse⁴⁰, Micol Romano⁴¹, natalie Roseenwasser²², T. Shawn Sato⁴², Gabriele Simonini⁴³, jennifer Soep¹⁸, Sara Stern⁴⁴, Alexander Theos⁴⁵, Lori Tucker⁴⁶, Leslie Vogel², Shima Yasin³⁰, Katerina Bouchalova⁴⁷, Alison Hendry⁴⁸, Kevin Cain⁴⁹, Hermann Girschick⁵⁰, Fatma Dedeoglu¹⁹, Christian Hedrich⁵¹, Ronald Laxer⁵², Polly Ferguson³⁰, Seza Ozen⁵³ and Yongdong Zhao⁵⁴, ¹Stanford University, Berkeley, CA, ²Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA, ³Riley Hospital for Children, Indiana University School of Medicine, Indianopolis, IN, ⁴Pediatric Rheumatology, Department of Pediatrics, University Hospital Carl Gustav Carus, Dresden, Germany, ⁵University of North Carolina School of Medicine, Chapel Hill, NC, ⁶University of Washington School of Medicine, Seattle, Seattle, WA, ⁷Seattle Children's Hospital, Seattle, ⁸ASST Gaetano Pini-CTO, Milan, Italy, Milan, Italy, ⁹Children's Hospital of The King's Daughters, Eastern Virginia Medical School, Norfolk, VA, ¹⁰Royal Children's Hospital, Melbourne, Australia, ¹¹Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, ¹²Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ¹³Unicamp, Campinas, SP, Brazil, ¹⁴Hacettepe University, Ankara, Turkey, ¹⁵Mayo Clinic, Rochester, MN, ¹⁶BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ¹⁷Sapienza University, Rome, Italy, ¹⁸University of Colorado School of Medicine, Aurora, CO, ¹⁹Boston Children's Hospital, Boston, MA, ²⁰Children's Mercy Hospital, Kansas City, MO, ²¹IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ²²University of Washington School of Medicine, Seattle, WA, ²³Dr. von Hauner Children´s Hospital, Munich, Germany, ²⁴Sanatorium for children Detskie Dyuny, Saint-Petersburg, Russia, ²⁵Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²⁶The University of North Carolina at Chapel Hill, Chapel Hill, NC, ²⁷Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ²⁸Hackensack University Medical Center, Montclair, NJ, ²⁹Stanford University School of Medicine, Palo Alto, CA, ³⁰Carver College of Medicine, University of Iowa Hospitals & Clinics, Iowa City, IA, ³¹Alder Hey Children's Hospital, Liverpool, United Kingdom, ³²ERN ReCONNET center, Meyer Children's Hospital-IRCCS, Firenze, Italy, ³³Mansoura University Hospital, Mansoura City, Egypt, ³⁴Science-Research Institute of Phthisiopulmonology, Saint-Petersburg, Russia, ³⁵Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, ³⁶HSS, New York, NY, ³⁷Patient Research Partner, Long Beach, CA, ³⁸Bristol Royal Hosp for Children, Bristol, United Kingdom, ³⁹IRCCS Giannina Gaslini, Genoa, Italy, ⁴⁰Seattle Children's Research institute, Seattle, WA, ⁴¹Behcet and Autoinflammatory Disease Center, Western University, London, ON, Canada, ⁴²University of Iowa, Iowa City, ⁴³Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, ⁴⁴University of Utah, Salt Lake City, UT, ⁴⁵Patient/parent partner, Washington DC, DC, ⁴⁶BC Children's Hospital, Vancouver, BC, Canada, ⁴⁷Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital, Olomouc, Czech Republic,⁴⁸Division of Medicine Middlemore Hospital Counties Manukau District Health, Auckland, New Zealand, ⁴⁹University of Washington, Seattle, WA, ⁵⁰Vivantes Clinic Friedrichshain, Berlin, Germany, ⁵¹University of Liverpool, Liverpool, United Kingdom, ⁵²SickKids, Toronto, ON, Canada, ⁵³Department of Pediatrics, Hacettepe University, Ankara, Turkey, ⁵⁴Seattle Children's Research institute, Seattle, WA
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease. The diagnosis of CNO is made by recognizing typical clinical and imaging presentation and excluding…
Abstract Number: 2664 • ACR Convergence 2024
BCMA-targeted Bispecific T Cell-engager Therapy of Autoimmune Disease
Laura Bucci¹, Melanie Hagen², Sebastian Boeltz², Danae-Mona Noethling², Tobias Rothe², Maria Gabriella Raimondo¹, Carlo Tur¹, Andreas Wirsching¹, Jochen Wacker¹, Aline Bozec¹, Georg Schett³ and Ricardo Grieshaber-Bouyer², ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Targeting B cells and plasma cells is a key therapeutic strategy in autoimmune disease(AID). Therapy with CD19-targeted chimeric antigen receptor (CAR) T-cells and bi-specific…
Abstract Number: 2641 • ACR Convergence 2024
Identification of Systemic Sclerosis Intrinsic Subtypes in the ASSET Clinical Trial Using PBC Gene Expression
Zhiyun Gong¹, Timothy Sullivan², Tammara Wood³, David Fox⁴, Dinesh Khanna⁵ and Michael Whitfield⁶, ¹Dartmouth College, Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Dartmouth, Hanover, NH, ⁴University of Michigan, Dexter, MI, ⁵University of Michigan, Ann Arbor, MI, ⁶Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic sclerosis (SSc) is molecularly heterogeneous and distinct subtypes of patients have been identified based on gene expression in skin. Although treatments have improved,…
Abstract Number: 2651 • ACR Convergence 2024
Vasculitis Associated with VEXAS Syndrome
Megan Sullivan¹, Kambiz Kalantari², Carolyn Mead-Harvey³, Yael Kusne⁴, Mrinal Patnaik², Abhishek Mangaonkar², Ronald Go², Daniel Montes², Kaaren Reichard², Horatiu Olteanu², Melanie Bois², Alexander Hines², Julio Sartori-Valinotti⁵, Kenneth Warrington² and Matthew Koster², ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Scottsdale, AZ, ⁴Mayo Clinic, Phoenix, AZ, ⁵Mayo Clinic, Rohester, MN
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently defined clinical entity that causes hematologic and autoinflammatory symptoms. Since its initial description…
Abstract Number: 2691 • ACR Convergence 2024
Transcriptomic Changes in CD4+ T Lymphocytes in Eosinophilic Granulomatosis with Polyangiitis
Roberto Ríos-Garcés¹, Núria Farran¹, Salvador Naranjo-Suarez², Roser Alba-Rovira¹, Sergio Prieto-González³, Itziar Tavera-Bahillo¹, Roser Solans-Laqué⁴, Ebymar Arismendi⁵, Marc Corbera-Bellalta¹, Javi Marco-Hernández¹, Farah Kamberovic¹, Nina Visocnik¹, Maria Cid⁶ and Georgina Espígol-Frigolé¹, ¹Vasculitis Research Group, Autoimmune Diseases Department, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain, ²Angiogenesis in Liver Disease Research Group, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain, ³Vasculitis Research Group, Autoimmune Diseases Department, IDIBAPS, Hospital Clinic, University of Barcelona, bar, Spain, ⁴Internal Medicine Service, Vall d'Hebron Hospital University and Campus, Barcelona, Spain, ⁵Pneumology Department, Hospital Clinic, IDIBAPS, University of Barcelona, CIBERES, Barcelona, Spain, ⁶Hospital Clinic Barcelona. University of Barcelona, Barcelona, Spain
Background/Purpose: Eosinophilic Granulomatosis with polyangiitis (EGPA) is a rare systemic autoimmune disorder, included within the ANCA-associated vasculitis. It is characterized by a diverse clinical profile,…
Abstract Number: 2694 • ACR Convergence 2024
Associations Between Immune Checkpoint Molecules and Nasal Microbiome in ANCA-associated Vasculitis
Yoichi Nakayama¹, Mirei Shirakashi², Erika Furukawa³, Chikako Endo⁴, Tsuneo Sasai⁵, Yuya Tabuchi⁴, Ryosuke Hiwa⁵, Hideaki Tsuji⁵, Koji Kitagori⁶, Shuji Akizuki⁷, Ran Nakashima⁵, Kosaku Murakami³, Hajime Yoshifuji⁵ and Akio Morinobu⁸, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Hirakata-shi, Osaka-fu, Japan, ²Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, ³Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan, ⁵Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁶Occupational Welfare Division, Agency for Health, Safety and Environment, Kyoto University,, Kyoto, Kyoto, Japan, ⁷Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, ⁸Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: Among patients with ANCA-associated vasculitis (AAV), several exhibit sinonasal involvement, especially in granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA). A recent…
Abstract Number: PP11 • ACR Convergence 2024
Living Well with Chronic Illness: Decades with MCTD
Carol KAMINSKI, HP (Hewlett Packard) Retired, Wilmington, NC
Background/Purpose: In the fall of 1985, I was not feeling well. I attributed my tiredness, weakness and malaise to stress and carried on. Walking upstairs I…
Abstract Number: PP10 • ACR Convergence 2024
Walking Away from Arthritis Pain: Exercise Helped Me Manage Sarcoidosis and Osteoarthritis Physically and Emotionally
Bridget Kelly, Hospital for Special Surgery, Rockville Centre, NY
Background/Purpose: In 2004, we moved to a new home with 2 small children, when I started experiencing terrible joint pain. For 2 years I was…
Abstract Number: PP14 • ACR Convergence 2024
Support Groups and Chronic Illness: Finding Social Support Among Peers
Alexandra Blumhorst¹ and Estela Mata-Carcamo², ¹Looms for Lupus, Silver Spring, MD, ²Looms for Lupus, Irwindale, CA
Background/Purpose: Like many lupus patients, my journey has been long, complex, and difficult. I began experiencing symptoms in 2019. Over the next five years, I…
Abstract Number: 2693 • ACR Convergence 2024
Risk Factors for Relapse in ANCA-Associated Vasculitis Among Patients with Relapse After Induction of Remission with Rituximab
Ellen Romich¹, Joshua Baker², Ian Green², Rennie Rhee², Carol McAlear², Ulrich Specks³, Rona Smith⁴, David Jayne⁴ and Peter Merkel², and the RITAZAREM Investigators, ¹University of Pennsylvania, Media, PA, ²University of Pennsylvania, Philadelphia, PA, ³Mayo Clinic, Rochester, MN, ⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Relapses are common in ANCA-associated vasculitis (AAV), both i) during maintenance treatment after induction of remission, and ii) after immunosuppressive treatment is discontinued. Relapses…
Abstract Number: PP09 • ACR Convergence 2024
Finding the Balance: Regaining My Strength While Living with Sjögren’s & POTS
Robert Fearon, Sjögren's Foundation, Reston, VA
Background/Purpose: Like many suffering from autoimmune diseases, my diagnosis was not straightforward and took nearly 13 years to get answers. I first started experiencing an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].